Author

David T. Ting

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

A Phase II Study of Nivolumab and Ipilimumab with Radiation Therapy in Patients with Metastatic, Microsatellite Stable Colorectal Cancer.

PURPOSE Immune checkpoint inhibitors (ICIs) have significantly altered the natural history of microsatellite instability high (MSI-H) colorectal cancer (mCRC). For microsatellite stable (MSS) refractory mCRC, ICIs recently demonstrated efficacy signals in patients without liver metastases. This study evaluated combined...

Leontios Pappas, J. Koenig, B. Yeap et al. · Clinical Cancer Research · 0 citations

Review Sep 2026

Abstract B033: Integrating spatial biology and peripheral blood biomarkers to map treatment resistance in pancreatic ductal adenocarcinoma

Despite recent advances in RAS-directed therapy, pancreatic ductal adenocarcinoma (PDAC) remains highly lethal. Surgical resection, chemotherapy, and radiotherapy continue to anchor treatment, but therapeutic resistance is pervasive, and most patients succumb to treatment-refractory residual disease. Advances in sing...

D. Olgun, Beatrice Awasthi, N. Lester et al. · Cancer Research · 0 citations

Sep 2026

Abstract A038: LINE-1 remodel pancreatic ductal adenocarcinoma metastatic plasticity

Retrotransposons comprise most of the human dark genome and are frequently upregulated during cancer progression. Long interspersed nuclear element-1 (LINE-1), the only autonomously active human retrotransposon, is aberrantly reactivated in pancreatic ductal adenocarcinoma (PDAC), yet how LINE-1 regulates metastatic...

Ching Ngar Wong, Fabricio R. Neira, Cristina Pedorella et al. · Cancer Research · 0 citations